secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2026-07-02T11:05:55+00:00
Accession:  0001193805-26-000910
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus signs $80M collaboration with Thermo Fisher for ARCT-032 CF program
----------------------------------------------------------------------------

- Thermo Fisher to provide up to $40M in clinical manufacturing services; Arcturus to spend up to $40M on CRO services via PPD.
- Collaboration supports Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
- Upon regulatory approval, Thermo Fisher receives exclusive commercial manufacturing rights for ARCT-032.
- Agreement includes technical transfer, clinical trial materials, PPQ batches, and stability studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/0001193805-26-000910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/e665618_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer